|
GB2148289B
(en)
|
1983-10-17 |
1987-09-23 |
Lilly Co Eli |
3-bicyclicpyridinium-methyl cephalosporins
|
|
US5468757A
(en)
*
|
1994-01-31 |
1995-11-21 |
Eli Lilly And Company |
6-azaindole thromboxane synthase inhibitors
|
|
AU747776B2
(en)
*
|
1998-10-30 |
2002-05-23 |
Merck & Co., Inc. |
Thrombin inhibitors
|
|
US6420382B2
(en)
|
2000-02-25 |
2002-07-16 |
Merck & Co., Inc. |
Tyrosine kinase inhibitors
|
|
US6809105B2
(en)
|
2000-04-27 |
2004-10-26 |
Abbott Laboratories |
Diazabicyclic central nervous system active agents
|
|
US7109208B2
(en)
|
2001-04-11 |
2006-09-19 |
Senju Pharmaceutical Co., Ltd. |
Visual function disorder improving agents
|
|
AR036040A1
(es)
|
2001-06-12 |
2004-08-04 |
Upjohn Co |
Compuestos de heteroarilo multiciclicos sustituidos con quinuclidinas y composiciones farmaceuticas que los contienen
|
|
KR100614900B1
(ko)
|
2001-10-02 |
2006-08-25 |
파마시아 앤드 업존 캄파니 엘엘씨 |
질병의 치료를 위한 아자비시클릭-치환된 융합-헤테로아릴화합물
|
|
US6849620B2
(en)
|
2001-10-26 |
2005-02-01 |
Pfizer Inc |
N-(azabicyclo moieties)-substituted hetero-bicyclic aromatic compounds for the treatment of disease
|
|
KR100974770B1
(ko)
|
2002-03-05 |
2010-08-06 |
일라이 릴리 앤드 캄파니 |
키나제 억제제로서의 퓨린 유도체
|
|
TW200406385A
(en)
|
2002-05-31 |
2004-05-01 |
Eisai Co Ltd |
Pyrazole compound and pharmaceutical composition containing the same
|
|
AU2003269413A1
(en)
|
2002-11-01 |
2004-05-25 |
Pharmacia & Upjohn Company Llc |
Nicotinic acetylcholine agonists in the treatment of glaucoma and retinal neuropathy
|
|
MXPA05004723A
(es)
|
2002-11-01 |
2005-12-05 |
Pharmacia & Upjohn Co Llc |
Compuestos que tienen ambas actividades del agonista alfa 7 nachr y el antagonista 5ht para el tratamiento de las enfermedades del snc.
|
|
KR20050085535A
(ko)
|
2002-12-11 |
2005-08-29 |
파마시아 앤드 업존 캄파니 엘엘씨 |
알파 7 니코틴성 아세틸콜린 수용체 아고니스트와 다른화합물의 조합물을 사용한 질환의 치료 방법
|
|
CN1735441A
(zh)
|
2002-12-11 |
2006-02-15 |
法玛西亚普强责任有限公司 |
治疗注意缺陷多动症的组合
|
|
EP1587511A2
(en)
|
2003-01-22 |
2005-10-26 |
Pharmacia & Upjohn Company LLC |
Treatment of diseases with alpha-7 nach receptor full agonists
|
|
EP1706384A1
(en)
|
2004-01-07 |
2006-10-04 |
AstraZeneca AB |
Therapeutic agents i
|
|
JP5069108B2
(ja)
|
2004-07-21 |
2012-11-07 |
メルク セローノ ソシエテ アノニム |
オクタヒドロピロロ［２，３，ｃ］ピリジン誘導体と、その医薬としての利用法
|
|
KR100958829B1
(ko)
|
2004-09-03 |
2010-05-25 |
주식회사유한양행 |
피롤로[2,3-ｃ]피리딘 유도체 및 그의 제조방법
|
|
CA2589127C
(en)
|
2004-12-08 |
2013-02-05 |
Johannes Gutenberg-Universitat Mainz |
3-(indolyl)-4-arylmaleimide derivatives and their use as angiogenesis inhibitors
|
|
EP1838706A1
(en)
|
2004-12-24 |
2007-10-03 |
Prosidion Limited |
G-protein coupled receptor agonists
|
|
US7557103B2
(en)
|
2005-04-05 |
2009-07-07 |
Eli Lilly And Company |
Imidazopyridazine compounds
|
|
US7777035B2
(en)
|
2005-06-22 |
2010-08-17 |
Chemocentryx, Inc. |
Azaindazole compounds and methods of use
|
|
SI1906965T1
(sl)
|
2005-06-22 |
2015-09-30 |
Chemocentryx, Inc. |
Azaindolne spojine in postopki uporabe
|
|
KR101142363B1
(ko)
|
2005-06-27 |
2012-05-21 |
주식회사유한양행 |
피롤로피리딘 유도체를 포함하는 항암제 조성물
|
|
CN101003537A
(zh)
|
2006-01-17 |
2007-07-25 |
上海恒瑞医药有限公司 |
吡咯并哒嗪类衍生物及其制备方法和用途
|
|
GB0705803D0
(en)
|
2007-03-28 |
2007-05-02 |
Glaxo Group Ltd |
Novel compounds
|
|
BRPI0809974A2
(pt)
|
2007-03-30 |
2014-10-07 |
Sanofi Aventis |
Compostos de pirimidina hidrazida como inibidores de pgds
|
|
AU2008241488A1
(en)
|
2007-04-16 |
2008-10-30 |
Merck Sharp & Dohme Corp. |
Bicyclic anilide heterocyclic CGRP receptor antagonists
|
|
WO2009041567A1
(ja)
*
|
2007-09-27 |
2009-04-02 |
Banyu Pharmaceutical Co., Ltd. |
メラニン凝集ホルモン受容体拮抗作用を有するジアリールケチミン誘導体
|
|
GB0803018D0
(en)
|
2008-02-19 |
2008-03-26 |
Cancer Rec Tech Ltd |
Therapeutic compounds and their use
|
|
EP2280968A2
(en)
|
2008-03-24 |
2011-02-09 |
Medivation Technologies, Inc. |
Pyrido [3, 4-b]indoles and methods of use
|
|
AR071717A1
(es)
|
2008-05-13 |
2010-07-07 |
Array Biopharma Inc |
Pirrolo[2,3-b]piridinas inhibidoras de quinasas chk1 y chk2,composiciones farmaceuticas que las contienen,proceso para prepararlas y uso de las mismas en el tratamiento y prevencion del cancer.
|
|
US8012992B2
(en)
|
2008-06-30 |
2011-09-06 |
Allergan, Inc. |
Aza-indoles and related compounds having sphingosine-1-phosphate (S1P) receptor antagonist biological activity
|
|
PL2308877T3
(pl)
|
2008-08-05 |
2014-07-31 |
Daiichi Sankyo Co Ltd |
Pochodne imidazopirydyn-2-onu
|
|
ATE542813T1
(de)
|
2008-08-06 |
2012-02-15 |
Pfizer |
6-substituierte 2- heterocyclylaminopyrazinverbindungen als chk-1- inhibitoren
|
|
US20110183975A1
(en)
|
2008-10-07 |
2011-07-28 |
Yasuhiro Goto |
Novel 6-azaindole aminopyrimidine derivatives having nik inhibitory activity
|
|
US8785489B2
(en)
|
2008-10-17 |
2014-07-22 |
Boehringer Ingelheim International Gmbh |
Heteroaryl substituted indole compounds useful as MMP-13 inhibitors
|
|
WO2010046780A2
(en)
|
2008-10-22 |
2010-04-29 |
Institut Pasteur Korea |
Anti viral compounds
|
|
CN101723936B
(zh)
|
2008-10-27 |
2014-01-15 |
上海睿星基因技术有限公司 |
激酶抑制剂及其在药学中的用途
|
|
MY153715A
(en)
|
2008-11-14 |
2015-03-13 |
Merial Ltd |
Enantiomerically enriched aryloazol-2-yl cyanoethylamino compounds, method of making and method of using thereof
|
|
WO2011096490A1
(ja)
|
2010-02-04 |
2011-08-11 |
第一三共株式会社 |
イミダゾピリジン－２－オン誘導体
|
|
JP2011178779A
(ja)
|
2010-02-04 |
2011-09-15 |
Daiichi Sankyo Co Ltd |
イミダゾピリジン−２−オン誘導体
|
|
EP2534156A1
(en)
*
|
2010-02-11 |
2012-12-19 |
OSI Pharmaceuticals, LLC |
7-aminofuropyridine derivatives
|
|
GB201017345D0
(en)
|
2010-10-14 |
2010-11-24 |
Proximagen Ltd |
Receptor antagonists
|
|
US9273028B2
(en)
|
2010-10-29 |
2016-03-01 |
Biogen Ma Inc. |
Heterocyclic tyrosine kinase inhibitors
|
|
CN102464654B
(zh)
|
2010-11-12 |
2016-01-13 |
上海泓博智源医药技术有限公司 |
抗病毒化合物
|
|
TWI501967B
(zh)
|
2010-12-16 |
2015-10-01 |
Janssen R&D Ireland |
作為呼吸道融合病毒抗病毒劑之氮雜吲哚類
|
|
CN103402996B
(zh)
|
2011-01-04 |
2015-02-11 |
诺瓦提斯公司 |
可用于治疗年龄相关性黄斑变性(amd)的吲哚化合物或其类似物
|
|
DE102011009961A1
(de)
|
2011-02-01 |
2012-08-02 |
Merck Patent Gmbh |
7-Azaindolderivate
|
|
WO2012106343A2
(en)
|
2011-02-01 |
2012-08-09 |
The Board Of Trustees Of The University Of Illinois |
Hdac inhibitors and therapeutic methods using the same
|
|
WO2012114252A1
(en)
|
2011-02-21 |
2012-08-30 |
Actelion Pharmaceuticals Ltd |
Novel indole and pyrrolopyridine amides
|
|
EP2694509B1
(en)
|
2011-04-05 |
2016-05-18 |
Pfizer Limited |
Pyrrolo[2,3-d]pyrimidine derivatives as inhibitors of tropomyosin-related kinases
|
|
WO2012178022A2
(en)
|
2011-06-24 |
2012-12-27 |
University Of Massachusetts |
Therapeutic applications targeting sarm1
|
|
UA111756C2
(uk)
|
2011-11-03 |
2016-06-10 |
Ф. Хоффманн-Ля Рош Аг |
Сполуки гетероарилпіридону та азапіридону як інгібітори тирозинкінази брутона
|
|
TWI577671B
(zh)
|
2011-11-14 |
2017-04-11 |
Sunshine Lake Pharma Co Ltd |
Aminoquinazoline derivatives and salts thereof and methods of use thereof
|
|
CN102532027A
(zh)
|
2012-03-01 |
2012-07-04 |
常州协丰医药研发有限公司 |
一种通过羟胺活化来形成吲唑衍生物的合成方法
|
|
CN102675310B
(zh)
|
2012-05-09 |
2014-12-24 |
林辉 |
制备吡唑并芳杂环化合物的方法
|
|
US20150336948A1
(en)
|
2012-05-29 |
2015-11-26 |
Merck Sharp & Dohme Corp. |
Isotopically Labeled Biaryl Urea Compounds
|
|
WO2014002053A1
(en)
|
2012-06-28 |
2014-01-03 |
Novartis Ag |
Pyrrolidine derivatives and their use as complement pathway modulators
|
|
EP2867229B1
(en)
|
2012-06-28 |
2017-07-26 |
Novartis AG |
Pyrrolidine derivatives and their use as complement pathway modulators
|
|
EA201590200A1
(ru)
|
2012-07-12 |
2015-08-31 |
Новартис Аг |
Модуляторы пути активации комплемента и их применение
|
|
SI2877467T1
(sl)
|
2012-07-26 |
2017-02-28 |
Glaxo Group Limited |
2-(azaindol-2-il)benzimidazoli kot PAD4 inhibitorji
|
|
AU2014248663A1
(en)
|
2013-03-12 |
2015-09-24 |
Abbvie Inc. |
Dihydro-pyrrolopyridinone bromodomain inhibitors
|
|
TWI663166B
(zh)
|
2013-04-24 |
2019-06-21 |
健生藥品公司 |
新化合物
|
|
JP6263606B2
(ja)
|
2013-05-02 |
2018-01-17 |
ファイザー・インク |
Ｐｄｅ１０阻害剤としてのイミダゾ−トリアジン誘導体
|
|
GB201310460D0
(en)
|
2013-06-12 |
2013-07-24 |
Lytix Biopharma As |
Compounds
|
|
FR3008975A1
(fr)
|
2013-07-23 |
2015-01-30 |
Servier Lab |
Nouveaux derives de pyrrole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
|
|
EP3110804A4
(en)
*
|
2014-02-25 |
2017-11-22 |
Achillion Pharmaceuticals, Inc. |
Carbamate, ester, and ketone compounds for treatment of complement mediated disorders
|
|
US9856264B2
(en)
|
2014-04-28 |
2018-01-02 |
Medshine Discovery Inc. |
Isoquinolinesulfonyl derivative as RHO kinase inhibitor
|
|
ES2666794T3
(es)
|
2014-06-13 |
2018-05-07 |
Bristol-Myers Squibb Company |
Compuestos tricíclicos como ligandos del receptor de alfa-7 nicotínico de acetilcolina
|
|
WO2015188368A1
(en)
|
2014-06-13 |
2015-12-17 |
Merck Sharp & Dohme Corp. |
Pyrrolo[2,3-c]pyridines as imaging agents for neurofibrilary tangles
|
|
ES2708965T3
(es)
|
2014-06-13 |
2019-04-12 |
Bristol Myers Squibb Co |
Compuestos tricíclicos como ligandos del receptor de alfa-7 nicotínico de acetilcolina
|
|
WO2016022624A1
(en)
|
2014-08-06 |
2016-02-11 |
California Institute Of Technology |
Silylation of aromatic heterocycles by earth abundant transition-metal-free catalysts
|
|
MX371153B
(es)
|
2014-10-23 |
2020-01-20 |
Janssen Pharmaceutica Nv |
Nuevos compuestos como inhibidores de la cinasa inductora de nf-kb (nik).
|
|
JP6616412B2
(ja)
|
2014-10-23 |
2019-12-04 |
ヤンセン ファーマシューティカ エヌ．ベー． |
Ｎｉｋ阻害剤としての新規のピラゾロピリミジン誘導体
|
|
WO2016095088A1
(en)
|
2014-12-15 |
2016-06-23 |
Merck Sharp & Dohme Corp. |
Erk inhibitors
|
|
WO2016095089A1
(en)
|
2014-12-15 |
2016-06-23 |
Merck Sharp & Dohme Corp. |
Erk inhibitors
|
|
US9938276B2
(en)
|
2014-12-19 |
2018-04-10 |
Merck Sharp & Dohme Corp. |
6,5-bicyclic octahydropyrrolopyridine orexin receptor antagonists
|
|
WO2016161571A1
(en)
|
2015-04-08 |
2016-10-13 |
Merck Sharp & Dohme Corp. |
Indazole and azaindazole btk inhibitors
|
|
WO2016180536A1
(en)
|
2015-05-13 |
2016-11-17 |
Selvita S.A. |
Substituted quinoxaline derivatives
|
|
BR112017028269A2
(pt)
|
2015-07-13 |
2018-09-04 |
Arvinas Inc |
composto, composição farmacêutica, uso de uma quantidade efetiva de um composto, estado ou condição de doença, e, método para identificar um composto.
|
|
DK3331886T3
(da)
|
2015-08-05 |
2020-08-24 |
Indivior Uk Ltd |
Dopamin-d3-receptorantagonister med en bicyclo-del
|
|
AR105809A1
(es)
|
2015-08-26 |
2017-11-08 |
Achillion Pharmaceuticals Inc |
Compuestos para el tratamiento de trastornos médicos
|
|
ES2908479T3
(es)
|
2015-08-26 |
2022-04-29 |
Achillion Pharmaceuticals Inc |
Compuestos para el tratamiento de trastornos inmunitarios e inflamatorios
|
|
AR106018A1
(es)
|
2015-08-26 |
2017-12-06 |
Achillion Pharmaceuticals Inc |
Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos
|
|
EP3389664A4
(en)
|
2015-12-14 |
2020-01-08 |
Raze Therapeutics Inc. |
MTHFD2 CAFFEIN INHIBITORS AND USES THEREOF
|
|
JP2019501222A
(ja)
|
2016-01-07 |
2019-01-17 |
シーエス ファーマテック リミテッド |
Ｅｇｆｒチロシンキナーゼの臨床的に重要な変異体の選択的阻害薬
|
|
TWI854164B
(zh)
|
2016-02-01 |
2024-09-01 |
美商百歐克斯製藥公司 |
苯并吡唑化合物及其類似物
|
|
CA3025220A1
(en)
|
2016-05-24 |
2017-11-30 |
Merck Patent Gmbh |
Tricyclic heterocylic derivatives
|
|
US20170355708A1
(en)
|
2016-06-09 |
2017-12-14 |
Cadent Therapeutics, Inc. |
Potassium channel modulators
|
|
CN110022875A
(zh)
*
|
2016-07-11 |
2019-07-16 |
莱福斯希医药公司 |
治疗性抑制化合物
|
|
US11357800B2
(en)
|
2016-08-16 |
2022-06-14 |
Henry Ford Health System |
Compositions for the treatment of neuropathic pain and sensitization of tumors to chemotherapies
|
|
IL292977A
(en)
|
2016-09-09 |
2022-07-01 |
Incyte Corp |
Pyrazolopyridine derivatives as modulators of hpk1 and their use in cancer therapy
|
|
EP3515426A1
(en)
|
2016-09-24 |
2019-07-31 |
Washington University |
INHIBITORS OF SARM1 NADase ACTIVITY AND USES THEREOF
|
|
CN109952303B
(zh)
|
2016-10-14 |
2022-10-21 |
林伯士拉克许米公司 |
Tyk2抑制剂及其用途
|
|
TWI764950B
(zh)
|
2016-11-02 |
2022-05-21 |
比利時商健生藥品公司 |
Ｐｄｅ２抑制劑
|
|
WO2018149986A1
(en)
|
2017-02-16 |
2018-08-23 |
Oryzon Genomics, S.A. |
2-(bicyclo-heteroaryl)-isonicotinic derivatives as histone demethylase inhibitors
|
|
WO2018170173A1
(en)
|
2017-03-15 |
2018-09-20 |
Metacrine, Inc. |
Farnesoid x receptor agonists and uses thereof
|
|
US20200131142A1
(en)
|
2017-03-15 |
2020-04-30 |
Metacrine, Inc. |
Farnesoid x receptor agonists and uses thereof
|
|
JP7174709B2
(ja)
|
2017-03-15 |
2022-11-17 |
メタクリン，インク． |
ファルネソイドｘ受容体アゴニストおよびその使用
|
|
WO2018210229A1
(zh)
|
2017-05-18 |
2018-11-22 |
南京明德新药研发股份有限公司 |
α-7尼古丁乙酰胆碱受体激动剂及应用
|
|
CN111278840B
(zh)
|
2017-08-18 |
2023-11-17 |
癌症研究科技有限公司 |
吡咯并[2，3-b]吡啶化合物及其治疗癌症的用途
|
|
WO2019106087A1
(en)
|
2017-11-29 |
2019-06-06 |
Syddansk Universitet |
Ampk inhibitors
|
|
US11332466B2
(en)
|
2017-12-01 |
2022-05-17 |
The Board Of Trustees Of The University Of Illinois |
Pyridinone-based epigenetic modifiers and uses thereof
|
|
AU2018379321B2
(en)
|
2017-12-05 |
2024-05-16 |
Oryzon Genomics, S.A. |
1,2,4-oxadiazole derivatives as histone deacetylase 6 inhibitors
|
|
US20200399268A1
(en)
|
2018-02-16 |
2020-12-24 |
UCB Biopharma SRL |
Pharmaceutical 6,5 Heterobicyclic Ring Derivatives
|
|
AR117398A1
(es)
|
2018-03-12 |
2021-08-04 |
Abbvie Inc |
Inhibidores de la señalización mediada por tirosina cinasa 2
|
|
US12103926B2
(en)
|
2018-03-27 |
2024-10-01 |
Ptc Therapeutics, Inc. |
Compounds for treating huntington's disease
|
|
JP2019182784A
(ja)
|
2018-04-10 |
2019-10-24 |
大日本住友製薬株式会社 |
ジヒドロピラゾロピラジノン誘導体
|
|
WO2019198024A1
(en)
|
2018-04-11 |
2019-10-17 |
VIIV Healthcare UK (No.5) Limited |
4-oxo-3,4-dihydroquinazoline compounds as inhibitors of human immunodeficiency virus replication
|
|
US11882759B2
(en)
|
2018-04-13 |
2024-01-23 |
Universal Display Corporation |
Organic electroluminescent materials and devices
|
|
JP7293343B2
(ja)
|
2018-05-09 |
2023-06-19 |
アプリノイア セラピューティクス リミテッド |
ヘテロアリール化合物及びその使用
|
|
CN112867489A
(zh)
|
2018-06-07 |
2021-05-28 |
达萨玛治疗公司 |
Sarm1抑制剂
|
|
CN112839647B
(zh)
|
2018-06-07 |
2025-09-23 |
达萨玛治疗公司 |
Sarm1抑制剂
|
|
AU2019319907B2
(en)
|
2018-08-09 |
2024-09-05 |
Valo Health, Inc. |
Carboxamides as ubiquitin-specific protease inhibitors
|